Lantheus Holdings, Inc. $LNTH Stock Position Increased by Isthmus Partners LLC

Isthmus Partners LLC raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 60.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,768 shares of the medical equipment provider’s stock after acquiring an additional 14,628 shares during the quarter. Isthmus Partners LLC’s holdings in Lantheus were worth $2,580,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Hantz Financial Services Inc. boosted its holdings in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 396 shares in the last quarter. First Horizon Corp bought a new position in shares of Lantheus in the third quarter valued at $26,000. Osterweis Capital Management Inc. acquired a new stake in shares of Lantheus during the 2nd quarter valued at $36,000. Farther Finance Advisors LLC lifted its position in shares of Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 275 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Lantheus during the 3rd quarter worth $55,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

LNTH stock opened at $93.91 on Friday. The firm has a 50 day moving average of $81.92 and a two-hundred day moving average of $70.39. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $98.27. The company has a market capitalization of $6.11 billion, a price-to-earnings ratio of 22.63 and a beta of -0.08. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same period last year, the business earned $1.53 EPS. The firm’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 4.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Wall Street Zen cut Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Mizuho lifted their target price on shares of Lantheus from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Jefferies Financial Group restated a “buy” rating and set a $110.00 price target on shares of Lantheus in a report on Tuesday, March 17th. Finally, B. Riley Financial restated a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.71.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.